CONMED (NYSE:CNMD) Posts Earnings Results, Beats Expectations By $0.14 EPS

CONMED (NYSE:CNMD) issued its earnings results on Wednesday. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.14, Zacks reports. CONMED had a net margin of 10.23% and a return on equity of 13.84%. CONMED updated its FY 2025 guidance to 4.250-4.400 EPS.

CONMED Price Performance

CNMD traded up $1.47 on Wednesday, hitting $74.35. 573,352 shares of the company’s stock were exchanged, compared to its average volume of 415,094. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of 17.66, a P/E/G ratio of 1.04 and a beta of 1.46. CONMED has a fifty-two week low of $61.05 and a fifty-two week high of $88.60. The firm has a 50-day moving average price of $70.62 and a 200-day moving average price of $70.19. The company has a current ratio of 2.27, a quick ratio of 1.06 and a debt-to-equity ratio of 1.01.

CONMED Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 3rd. Stockholders of record on Friday, December 20th were given a $0.20 dividend. The ex-dividend date of this dividend was Friday, December 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.08%. CONMED’s dividend payout ratio (DPR) is presently 19.00%.

Analysts Set New Price Targets

CNMD has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $97.00 target price on shares of CONMED in a research note on Thursday, October 31st. StockNews.com cut CONMED from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $79.80.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.